Replies to post #210756 on Biotech Values

[DewDiligence]

GILD reports phase-2 GS-0976 data in NASH:

https://finance.yahoo.com/news/gilead-announces-phase-2-results-123600277.html

The data demonstrate that the higher dose of GS-0976 (20 mg taken orally once daily) when administered for 12 weeks was associated with statistically significant reductions in hepatic steatosis (buildup of fat in the liver) and a noninvasive marker of fibrosis (TIMP-1) compared to placebo.

Patients in this trial had fibrosis stage F1-F3, according to either a biopsy or an MRE/MRI. The lower dose tested, 5mg, did not show efficacy.

GILD picked up GS-0976 in the 2016 acquisition of (private) Nimbus Therapeutics for $400M up-front (#msg-121656679). It is one of several NASH candidates owned by GILD.